Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

International Journal of Impotence Research, Published online: 22 March 2024; doi:10.1038/s41443-024-00872-zResponse to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

https://www.nature.com/articles/s41443-024-00872-z

Source: International Journal of Impotence Research - March 22, 2024 Category: Urology & Nephrology Authors: Emil Durukan Christian Fuglesang Skj ødt Jensen Mikkel Fode Source Type: research

More News: Impotence | Pain | Urology & Nephrology